Furosemide-Digoxin vs. Polidocanol for Cutaneous Warts

A Head-to-Head Comparison of Intralesional Furosemide-Digoxin Versus Polidocanol for the Treatment of Cutaneous Warts With 6-Month Follow-up

This study compares the effectiveness and safety of two different intralesional treatments for cutaneous warts: a combination of furosemide and digoxin versus polidocanol.

This is a prospective, randomized, single-blind, comparative clinical study to evaluate the efficacy and safety of intralesional combined furosemide-digoxin versus intralesional polidocanol in the treatment of cutaneous warts. Sixty-four adult patients were randomized to receive one of the two treatments every two weeks for a maximum of four sessions. The main goal was to see which treatment was better at completely clearing the warts. The study also looked at side effects and how often the warts came back within six months.

Inclusion Criteria:

• Patients over 18 years of age with single or multiple cutaneous warts.

Exclusion Criteria:

• History of allergies to the study medications, known cardiac or renal disease, hypertension, pregnancy or lactation, and any signs of systemic or local infection.